JP2002521329A - フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理 - Google Patents

フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理

Info

Publication number
JP2002521329A
JP2002521329A JP2000560887A JP2000560887A JP2002521329A JP 2002521329 A JP2002521329 A JP 2002521329A JP 2000560887 A JP2000560887 A JP 2000560887A JP 2000560887 A JP2000560887 A JP 2000560887A JP 2002521329 A JP2002521329 A JP 2002521329A
Authority
JP
Japan
Prior art keywords
formula
compound
group
pharmaceutical composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000560887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002521329A5 (enExample
Inventor
スタニスロー、アール、バージンスキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2002521329A publication Critical patent/JP2002521329A/ja
Publication of JP2002521329A5 publication Critical patent/JP2002521329A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000560887A 1998-07-23 1999-07-02 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理 Pending JP2002521329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/121,567 1998-07-23
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010228241A Division JP2011051993A (ja) 1998-07-23 2010-10-08 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理

Publications (2)

Publication Number Publication Date
JP2002521329A true JP2002521329A (ja) 2002-07-16
JP2002521329A5 JP2002521329A5 (enExample) 2006-08-17

Family

ID=22397538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000560887A Pending JP2002521329A (ja) 1998-07-23 1999-07-02 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理
JP2010228241A Withdrawn JP2011051993A (ja) 1998-07-23 2010-10-08 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010228241A Withdrawn JP2011051993A (ja) 1998-07-23 2010-10-08 フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100417100B1 (enExample)
CN (3) CN1191064C (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DE60115465T2 (de) 2000-08-29 2006-08-03 Nobex Corp. Immunoregulierende verbindungen, deren derivate und ihre verwendung
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
EP1773767B1 (en) 2004-07-07 2016-03-09 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
JP2008508300A (ja) * 2004-07-28 2008-03-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌剤としての３−ブロモ−２−オキソプロピオン酸プロピルおよび誘導体
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
DK3263100T3 (da) 2009-04-03 2020-05-11 Ocera Therapeutics Inc L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf
AU2010258888B2 (en) 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
MX360062B (es) 2010-10-06 2018-10-22 Ocera Therapeutics Inc Metodos de elaboracion de fenilacetato de l-ornitina.
CN107206021B (zh) 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
EP3397960B1 (en) * 2015-12-30 2020-01-29 Société des Produits Nestlé S.A. Method for determining fat free body mass
US10624869B2 (en) 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
CN110740988A (zh) 2017-05-11 2020-01-31 欧塞拉治疗有限公司 制备l-鸟氨酸苯乙酸盐的方法
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
KR20230124107A (ko) * 2017-06-12 2023-08-24 스탠니슬로우 알 벌진스키 연수막 질환의 치료 방법
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) * 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
WO1993024123A1 (en) * 1992-05-27 1993-12-09 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
ATE310505T1 (de) 1996-05-14 2005-12-15 Stanislaw R Burzynski Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) * 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
WO1993024123A1 (en) * 1992-05-27 1993-12-09 Burzynski Stanislaw R Methods for treating viral infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER, vol. 75(12), JPN7010001009, 1995, pages 2932 - 2938, ISSN: 0001588447 *
DRUGS EXPTL. CLIN. RES., vol. 12(SUPPL.1), JPN6010018058, 1986, pages 47 - 55, ISSN: 0001588444 *
DRUGS EXPTL. CLIN. RES., vol. 12(SUPPL.1), JPN6010018059, 1986, pages 17 - 24, ISSN: 0001588445 *
DRUGS EXPTL. CLIN. RES., vol. 12(SUPPL.1), JPN6010018060, 1986, pages 25 - 35, ISSN: 0001588446 *
KURUME MED. J., vol. 43(2), JPN6010019244, 1996, pages 137 - 147, ISSN: 0001588443 *

Also Published As

Publication number Publication date
EA200100168A1 (ru) 2001-08-27
ZA200100622B (en) 2002-06-26
WO2000004894A3 (en) 2000-04-27
US20010044466A1 (en) 2001-11-22
DE69914084T2 (de) 2004-10-28
BR9912356A (pt) 2001-04-17
CA2336945A1 (en) 2000-02-03
DE69914084D1 (de) 2004-02-12
PT1098643E (pt) 2004-05-31
US6258849B1 (en) 2001-07-10
JP2011051993A (ja) 2011-03-17
IL140848A0 (en) 2002-02-10
EP1098643B1 (en) 2004-01-07
KR20030027089A (ko) 2003-04-03
KR20030027088A (ko) 2003-04-03
CN100400039C (zh) 2008-07-09
KR100414587B1 (ko) 2004-01-13
KR100417101B1 (ko) 2004-02-05
KR20010071025A (ko) 2001-07-28
KR100399658B1 (ko) 2003-09-29
PL345959A1 (en) 2002-01-14
NZ509244A (en) 2004-02-27
KR20030027087A (ko) 2003-04-03
ATE257378T1 (de) 2004-01-15
EA004179B1 (ru) 2004-02-26
CN1319010A (zh) 2001-10-24
CA2336945C (en) 2008-11-18
PL213698B1 (pl) 2013-04-30
HK1037142A1 (en) 2002-02-01
WO2000004894A2 (en) 2000-02-03
CN1191064C (zh) 2005-03-02
CN1660061A (zh) 2005-08-31
DK1098643T3 (da) 2004-05-24
ID28160A (id) 2001-05-10
EP1098643A2 (en) 2001-05-16
ES2214866T3 (es) 2004-09-16
AU759278B2 (en) 2003-04-10
CN1605334A (zh) 2005-04-13
AU4854299A (en) 2000-02-14
US6943192B2 (en) 2005-09-13
KR100417100B1 (ko) 2004-02-05
IL140848A (en) 2005-05-17

Similar Documents

Publication Publication Date Title
JP2002521329A (ja) フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理
OA11924A (en) Methods for treatment of sickle cell anemia.
JP2023109937A (ja) ３－置換１，２，４－オキサジアゾールの結晶形態
JP2002506816A (ja) ケト酸及びアミン誘導体の塩、及び医薬品調製を目的としたそれらの利用
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
CN111803489A (zh) 含笑内酯及其衍生物在垂体腺瘤治疗中的应用
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
US10507228B2 (en) Methods and compositions related to KRAS inhibitors
US4918193A (en) Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion
US7226766B2 (en) S-methylcysteine, S-ethylcysteine, and related S-alkylthiols as antagonists to the effects of S-nitrosothiols and nitric oxide
JPH08501796A (ja) イブプロフェン−カフェイン配合物
JP4428481B2 (ja) 神経因性疼痛治療剤
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
CN115300511A (zh) 一种组合物的医药用途
JPS61129124A (ja) 抗腫瘍剤
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100709

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100809

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110812